ABSTRACT
Avian influenza viruses (AIV) affect many species of birds including waterfowl and may persist in sediment in aquatic habitats. Sediment samples were collected from two areas representative of prime migration and overwintering waterfowl habitat in Dorchester County, Maryland in the fall and winter of 2013-2014. Samples were screened for the presence of AIV via reverse transcriptase-quantitative PCR targeting the matrix gene. Although 13.6% of sediment samples were positive for the AIV matrix gene across all collection dates and locations, differences in detection were noted with location and collection season. Percentage of AIV-positive sediment samples recovered corresponded to trends in waterfowl abundance at collection sites both temporally and spatially. These findings provide further support for the assertion that the presence of AIV in the aquatic environment is likely affected by the total number, site-specific density, and array of waterfowl species.
Subject(s)
Environmental Monitoring , Geologic Sediments/virology , Influenza A virus/isolation & purification , Animals , Anseriformes , Maryland , Reverse Transcriptase Polymerase Chain Reaction/veterinary , Viral Matrix Proteins/analysisSubject(s)
Fish Diseases/microbiology , Mycobacterium Infections/veterinary , Mycobacterium/genetics , Perciformes , Animals , Female , Male , Mycobacterium/classification , Mycobacterium/isolation & purification , Mycobacterium Infections/microbiology , Phylogeny , RNA, Bacterial/genetics , RNA, Ribosomal, 23S/genetics , Sequence Analysis, DNA/veterinary , VirginiaABSTRACT
Eighty striped bass Morone saxatilis were obtained from Delaware Bay using commercial gill nets set adjacent to Woodland Beach (n = 70) and Bowers Beach (n = 10) in December 2003. Fish were examined for gross lesions. Total lengths (TLs) and eviscerated weights were determined to calculate condition factors (K). Portions of spleens were aseptically harvested for bacterial culture, and portions of spleens, kidneys (anterior and posterior), livers, and gonads were obtained for histological examination. The size distribution of the striped bass was relatively homogeneous; the mean TL was about 600 mm for all samples. Mean K exceeded 0.95 in all samples and was not significantly different (P > 0.05) among samples. Significant differences in mycobacterial infection prevalence (P < or = 0.05) were observed among samples; samples obtained at Woodland Beach (WB) on December 10 (53.8%, n = 13) and December 17 (7.1%, n = 42) exhibited the most striking differences in prevalence. Mycobacterial infection intensity ranged from 1 X 10(2) to 1 X 10(7) colony-forming units per gram of spleen. Acanthocephalan infection prevalence and intensity, non-acid-fast bacterial infection prevalence, and fish sex ratio were also significantly different among the samples (P < or = 0.05). Similar to the mycobacterial infections, differences in sex ratio, acanthocephalan infection, and non-acid-fast bacterial infection were observed between the WB samples taken on December 10 and 17. However, no significant associations (P > 0.05) were observed between sex ratio or these infections and mycobacterial infection. The differences in bacterial and parasite infection prevalence and intensity and fish sex ratio in some samples indicate that these fish had a different history and that the epizootiology of mycobacterial infection in striped bass from Delaware Bay may be relatively complex.
Subject(s)
Bass/microbiology , Fish Diseases/epidemiology , Mycobacterium Infections/veterinary , Animals , Colony Count, Microbial/veterinary , Delaware/epidemiology , Female , Fish Diseases/pathology , Gonads/pathology , Kidney/pathology , Liver/pathology , Male , Mycobacterium/isolation & purification , Mycobacterium Infections/epidemiology , Mycobacterium Infections/pathology , Prevalence , Sex Factors , Spleen/pathologyABSTRACT
The susceptibility of lake trout Salvelinus namaycush, rainbow trout Oncorhynchus mykiss and Atlantic salmon Salmo salar to Myxobolus cerebralis, the causative agent of whirling disease, was compared in controlled laboratory exposures. A total of 450 (225 for each dose) fry for each species were exposed to a low (200 spores per fish) or high (2000 spores per fish) dose of the infective triactinomyxon. At 22 wk post-exposure, 60 fish from each group, as well as controls for each species, were examined for clinical signs (whirling behavior, blacktail, deformed heads and skeletal deformities), microscopic lesions, and presence of spores. Rainbow trout were highly susceptible to infection, with 100% being positive for spores and with microscopic pathological changes in both exposure groups. Rainbow trout were the only species to show whirling behavior and blacktail. Atlantic salmon were less susceptible, with only 44 and 61% being positive for spores, respectively, in the low and high dose groups, while 68 and 75%, respectively, had microscopic pathology associated with cartilage damage. Rainbow trout heads contained mean spore concentrations of 2.2 (low dose) or 4.0 (high dose) x 10(6) spores g tissue(-1). The means for positive Atlantic salmon (not including zero values) were 1.7 (low) and 7.4 (high) x 10(4) spores g tissue(-1). Lake trout showed no clinical signs of infection, were negative for spores in both groups and showed no histopathological signs of M. cerebralis infection.
Subject(s)
Eukaryota/pathogenicity , Fish Diseases/parasitology , Protozoan Infections, Animal/pathology , Protozoan Infections, Animal/physiopathology , Analysis of Variance , Animals , Disease Susceptibility/veterinary , Fish Diseases/pathology , Fish Diseases/physiopathology , Head/pathology , Histological Techniques , SalmonidaeABSTRACT
Growth inhibition of established tumor metastases in the lungs poses a difficult challenge for most clinical settings in spite of extensive multi-modality approaches. Aerosol delivery of drugs and genes holds promise for the treatment of disseminated lung metastases, since aerosol delivery can target the lungs specifically and uniformly. We previously demonstrated that aerosol delivery of dilauroylphosphatidylcholine liposome formulation of 9-nitrocamptothecin (9NC-DLPC) inhibits B16-F10 melanoma lung metastases. Aerosol delivery of polyethleneimine-p53 DNA (PEI-p53) complexes results in a similar anti-tumor effect in the B16-F10 model. In both these previous studies, the protocols were designed to inhibit development of lung metastases. In this study we demonstrate, using the B16-F10 melanoma lung metastasis model, that sequential aerosol delivery of PEI-p53 and 9NC-DLPC acts additively to inhibit growth of established B16-F10 tumor metastases in the lungs. Mice injected with B16-F10 cells and treated with a combination of 9NC-DLPC (twice weekly) and PEI-p53 (once weekly) aerosol complexes starting on day 11 after tumor inoculation, exhibited a highly significant (P < 0.01) reduction in the number of visible tumor foci as compared with untreated mice or mice treated with either single agent alone, or with a combination of 9NC and a control plasmid. There was a highly significant reduction in the tumor burden, as well as the lung weights for the 9NC and p53 combination group (P < 0.001 as compared with other groups). Moreover, the doses of p53 gene and 9NC in the combination group were reduced at least two-fold as compared with our previous single agent studies, but still achieved significant tumor inhibition. Furthermore, the sequential aerosol delivery of p53 and 9NC lead to a 30-40% increase in the mean survival time of these mice, as compared with animals in different control groups. The data suggest that the combination of 9NC and p53 gene delivered by aerosol is an attractive strategy for growth inhibition of established tumor metastases in the lungs.
Subject(s)
Camptothecin/analogs & derivatives , Genes, p53 , Genetic Therapy/methods , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Melanoma/secondary , Melanoma/therapy , Aerosols , Animals , Antineoplastic Agents/administration & dosage , Camptothecin/administration & dosage , Combined Modality Therapy , Liposomes , Lung Neoplasms/drug therapy , Melanoma/drug therapy , Mice , Mice, Inbred C57BL , Neoplasms, Experimental/therapy , Survival RateABSTRACT
Delivery of genes to the lung has enormous potential in a wide variety of illnesses, from lung cancer to genetic deficiency diseases. Many delivery systems have been utilized, each with its own advantages and limitations. Polyethylenimine is a polycation capable of binding and compacting DNA, enabling intravascular plasmid delivery to normal tissues in such a way that the plasmid can be expressed in a proportion of the exposed cells. We have developed a novel intravenous method to deliver small amounts of plasmid to lung tissue, using nontoxic quantities of polyethylenimine in combination with albumin (or other soluble proteins). Injection of 1 microg or less of plasmid resulted in highly efficient gene expression in lung interstitial and endothelial tissues (0.5 to 1 ng luciferase per microg plasmid DNA), while larger quantities of plasmid reduced relative gene expression. Using luciferase as a reporter gene, single injections had maximal gene expression between 24 and 48 h, with a rapid decline thereafter. In contrast to some other delivery systems, however, no inhibition of gene expression occurred during multiple rounds of plasmid administration through 20 days. As a result, this method may have useful applications in diseases that could benefit from recurrent therapeutic gene delivery.
Subject(s)
Genetic Therapy/methods , Lung Diseases/therapy , Plasmids , Polyethyleneimine , Serum Albumin/genetics , Animals , Female , Gene Expression , Genetic Vectors/administration & dosage , Humans , Injections, Intravenous , Luciferases/genetics , Male , Mice , Mice, Inbred BALB C , Time Factors , Tissue Distribution , Transfection/methodsABSTRACT
Lung metastases are a frequent complication of osteosarcoma and a treatment that would reduce the severity of this complication would be of great benefit to patients. We have used a formulation consisting of polyethyleneimine (PEI) and a p53 gene administered in aerosol to treat established lung micrometastases as a model of human osteosarcoma in nude mice. The SAOS-LM6 cell line, a metastatic derivative of the p53 null SAOS-2 line, expresses high levels of p53 protein after in vitro transfection with PEI-p53 complexes as determined by ELISA, and transfection with both p53wt and the p53 variant, p53-CD(1-366) in vitro, results in a marked inhibition of SAOS-LM6 cell proliferation. Aerosol delivery of plasmid DNA containing either the p53 gene or a p53-CD(1-366) variant gene formulated with PEI to mice resulted in highly significant reductions in the numbers and size of tumors (P<.001), the total number of tumor foci in the lungs (P<.001) and the size of individual tumor nodules in treated animals compared to untreated, PEI only-treated and PEI-CAT-treated control animals. The different tissues examined did not reveal any signs of toxicity or inflammation after repeated exposure to PEI-DNA. The aerosol delivery of PEI-based formulations of p53 or synthetic p53 variant genes represents a promising new strategy for the treatment of established human osteosarcoma lung metastases. The noninvasive nature of aerosol delivery coupled with low toxicity also make this therapeutic approach potentially appropriate for combination therapy with either radio- or chemotherapy.
Subject(s)
Genes, p53/genetics , Genetic Therapy/methods , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Osteosarcoma/secondary , Osteosarcoma/therapy , Administration, Inhalation , Aerosols , Animals , Bone Neoplasms/pathology , Bone Neoplasms/therapy , Cell Division/drug effects , DNA/genetics , Enzyme-Linked Immunosorbent Assay , Genetic Vectors , Humans , Immunoenzyme Techniques , Lung Neoplasms/metabolism , Male , Mice , Mice, Nude , Neoplasm Transplantation , Osteosarcoma/metabolism , Polyethyleneimine/pharmacology , Specific Pathogen-Free Organisms , Transfection , Tumor Cells, Cultured/drug effectsABSTRACT
Gene therapy targeted at the respiratory epithelium holds therapeutic potential for diseases such as cystic fibrosis and alpha-1 anti-trypsin deficiency. A variety of approaches such as intranasal or intratracheal instillation and aerosol delivery have been utilized to target genes to the airways. Polyethylenimine (PEI), a linear or branched polycationic polymer, has been used for delivery of genes to various organs. In this study, using fluorescein isothiocyanate (FITC)-labeled branched PEI, we initially examined the localization of PEI in the lungs after aerosol delivery to Balb/C mice. Further, after aerosol delivery of PEI-CAT DNA, in situ immunostaining for chloramphenicol acetyl transferase (CAT) protein was used to localize the transgene expression within the lungs. Immunohistochemistry for CAT, as well as localization of FITC-labeled PEI, revealed that after aerosol delivery, the PEI-DNA complexes deposit and subsequently transfect most of the epithelial cells in the conducting airways (including the peripheral airways). High levels of CAT were detected at 24 h after aerosol exposure and significant CAT expression was detected in the lungs up to 28 days after a single aerosol exposure. The data suggest that aerosol delivery of PEI-DNA complexes could be effective for the treatment of pulmonary diseases such as cystic fibrosis and alpha-1 anti-trypsin deficiency.
Subject(s)
Administration, Inhalation , Epithelium/metabolism , Fluorescein-5-isothiocyanate/pharmacology , Lung/metabolism , Polyethyleneimine/therapeutic use , Transgenes , Animals , Chloramphenicol O-Acetyltransferase/metabolism , Cystic Fibrosis/therapy , Drug Delivery Systems , Epithelial Cells/metabolism , Female , Fluorescent Dyes/pharmacology , Immunohistochemistry , In Situ Hybridization , Mice , Mice, Inbred BALB C , Microscopy, Fluorescence , Time Factors , Transfection , alpha 1-Antitrypsin Deficiency/therapyABSTRACT
Pulmonary gene therapy with nonviral vectors delivered by instillation or intravenously has typically been associated with co-induction of cytokine responses attributed to the CpG motifs in the bacterial plasmid. Alternative delivery systems are being developed to circumvent the cytokine responses to the plasmid. Aerosol delivery of polyethylenimine--DNA (PEI-DNA) complexes leads to localized, high levels of transgene expression in the lungs. In this study, we show that PEI-DNA aerosol delivery is also associated with induction of tumor necrosis factor alpha (TNF-alpha) and interleukin 1 beta (IL-1 beta) in the lung and bronchoalveolar lavage fluid (BALF). However, there is no increase in the serum levels of these cytokines. The levels of these cytokines peak at 5--8 h after aerosol exposure for lung tissue, and at 24 h for BALF. However, the levels detected are much lower than those observed when PEI-DNA complexes, guanidinium--cholesterol: dioleoylphosphatidyl--ethanolamine liposome--DNA (BGTC:DOPE--DNA) complexes or 1,2-dioleoyl-sn-glycero-3-trimethylammonium--propane--cholesterol:DNA (DOTAP-Chol:DNA) complexes were delivered intravenously. Also, the lung cytokine levels were higher when BGTC:DOPE--DNA complexes were delivered by aerosol to the mice. Although the mechanism remains to be elucidated, the data suggest that aerosol exposure to PEI--DNA complexes can achieve high levels of transgene expression in the lungs without inducing high levels of cytokine responses.
Subject(s)
Cytokines/biosynthesis , DNA, Bacterial/immunology , Genetic Therapy/methods , Lung/immunology , Polyethyleneimine , Administration, Inhalation , Aerosols , Animals , Bronchoalveolar Lavage Fluid/immunology , Cytokines/blood , DNA, Bacterial/genetics , Female , Mice , Mice, Inbred C57BL , Plasmids/immunology , TransgenesABSTRACT
Hematological responses to whirling disease in rainbow trout (Oncorhynchus mykiss) were investigated. Two-mo-old fingerling rainbow trout were exposed to cultured triactinomyxon spores of Myxobolus cerebralis at 9,000 spores/fish in December, 1997. Twenty-four wks post-exposure, fish were taken from infected and uninfected groups for peripheral blood and cranial tissue sampling. Histological observations on cranial tissues confirmed M. cerebralis infection in all exposed fish. Differences in hematological parameters between the two groups included significantly lower total leukocyte and small lymphocyte counts for the infected fish. No effects on hematocrit, plasma protein concentration, or other differential leukocyte counts were noted.
Subject(s)
Fish Diseases/blood , Fish Diseases/parasitology , Oncorhynchus mykiss/blood , Oncorhynchus mykiss/parasitology , Protozoan Infections, Animal/blood , Animals , Body Weight , Brain/parasitology , Eukaryota/isolation & purification , Lymphocyte Count/veterinary , Lymphopenia/blood , Lymphopenia/veterinaryABSTRACT
Mutations in the p53 tumor suppressor gene and the pathways mediated by the p53 protein are common in many human cancers. Replacement of functional p53 by gene therapy is a potential way of combating these cancers and the associated drug resistance and tumor growth. Aerosol delivery of genes is a noninvasive way of targeting genes to the lung for gene therapy. Here we demonstrate, using a murine melanoma lung metastasis model, that aerosol delivery of polyethyleneimine-p53 (PEI-p53) complexes inhibits the growth of lung metastasis. A significantly reduced number of visible foci were observed in C57BL/6 mice injected with B16-F10 melanoma and treated with PEI-p53 complexes by aerosol for 3 weeks at twice a week. Fifty percent of the mice in the PEI-p53-treated group exhibited no visible tumor foci. There was a significant reduction in the lung weights of p53-treated mice (P < 0.01) compared to control groups. The tumor burden was also significantly lower (P < 0.001) in mice treated with PEI-p53 complexes. No extrapulmonary metastasis was observed in the groups treated with PEI-p53 complexes compared to 50% of the mice in control groups, which showed metastasis to lymph nodes in the neck or abdomen. Treatment with PEI-p53 aerosol also led to about a 50% increase in the mean length of survival of the mice injected with B16-F10 cells. These data suggest that delivery of the p53 gene by aerosol using PEI as the gene delivery vector can inhibit the growth of lung metastasis.
Subject(s)
Administration, Inhalation , Genes, p53 , Genetic Therapy/methods , Lung Neoplasms/prevention & control , Melanoma, Experimental/prevention & control , Animals , Cell Division/drug effects , Female , Genetic Vectors , Humans , Injections, Intravenous , Luciferases/biosynthesis , Lung Neoplasms/metabolism , Lung Neoplasms/secondary , Lymph Nodes/drug effects , Lymph Nodes/metabolism , Lymph Nodes/pathology , Lymphatic Metastasis , Melanoma, Experimental/metabolism , Melanoma, Experimental/secondary , Mice , Mice, Inbred C57BL , Polyethyleneimine , Survival Rate , Transfection , Tumor Cells, Cultured , Tumor Suppressor Protein p53/biosynthesisABSTRACT
Aerosol delivery of plasmid DNA to the lungs offers the possibility of direct application of gene preparations to pulmonary surfaces as a means of treating a variety of genetic pulmonary disorders. However, the process of jet nebulization rapidly degrades naked DNA, viral vectors, and many lipid-based formulations. While complexing DNA with cationic lipids has been shown to significantly stabilize plasmid DNA, losses of biological activity often occur during nebulization, severely limiting the efficiency of aerosol delivery of many such complexes. In conjunction with the design of aerosol delivery systems appropriate for DNA delivery, we have developed formulations using polyethyleneimine (PEI, a polycationic polymer) and DNA that result in a high level of pulmonary transfection (10- to 100-fold greater than many cationic lipids) and are stable during nebulization. In addition, these PEI-based formulations exhibit a high degree of specificity for the lungs. The properties of PEI-based formulations that make them resistant to nebulization and efficient as DNA delivery vectors for pulmonary sites have been investigated. Potential applications of this technology, including the use of aerosolized PEI-DNA for genetic immunization, are discussed.
Subject(s)
Aerosols , DNA/administration & dosage , DNA/genetics , Gene Transfer Techniques , Genetic Therapy/methods , Polyethyleneimine/pharmacology , Animals , Antibody Formation/genetics , Cations , Gene Expression , Genetic Vectors/administration & dosage , Humans , Lipids/genetics , Mice , Mice, Inbred BALB C , Nebulizers and Vaporizers , Plasmids/genetics , Time Factors , Transfection , Tumor Cells, CulturedABSTRACT
Aerosol gene delivery to the pulmonary system has vast potential for many diseases, including cystic fibrosis and lung cancer. We recently reported that polyethyleneimine (PEI), a cationic polymer, holds promise as a gene delivery vector for transfection in lung by aerosol. To further optimize the gene expression in the lung by aerosol, we utilized 5% CO(2) in air for the nebulization of PEI-DNA complexes. Five percent CO(2)-in-air gave a threefold higher gene expression compared to normal air using the chloramphenicol acetyl transferase (CAT) reporter gene delivered by Aerotech II nebulizer. The delivery of DNA by PEI was dose dependent with the highest expression obtained when 2 mg of DNA in 10 ml was nebulized at a PEI nitrogen:DNA phosphate (N:P) ratio of 10:1. The optimal N:P ratio for lung transfection was found to be between 10:1 and 20:1 using the CAT and luciferase reporter genes. The time-course studies showed the highest expression at 24 h after aerosol delivery and 40-50% of peak level was detectable even after a week. Tissue distribution indicates the expression to be specific to the lung with no detectable expression in any other tissue examined. Histological and biochemical analysis of lungs revealed no evidence of acute inflammation.
Subject(s)
Aerosols , Genetic Therapy/methods , Genetic Vectors/administration & dosage , Lung/metabolism , Polyethyleneimine , Animals , Carbon Dioxide/metabolism , Chloramphenicol O-Acetyltransferase/metabolism , DNA/administration & dosage , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Female , Gene Expression , Luciferases/metabolism , Lung/pathology , Mice , Mice, Inbred BALB C , Peroxidase/metabolism , Plasmids/metabolism , Time Factors , Tissue Distribution , TransgenesABSTRACT
Genetic immunization is a novel form of vaccination in which transgenes are delivered into the host to produce the foreign protein within host cells. Although systemic immune responses have been relatively easy to induce by genetic immunization, the induction of regional and mucosal immunity has often been more challenging. To address the problem of eliciting mucosal immunity in the lung, we utilized macroaggregated albumin to target plasmid DNA to the lung. Macroaggregated albumin is trapped in the lung after i. v. injection, and it is routinely used in radiolabeled form as an imaging modality to evaluate pulmonary blood flow. To couple DNA to this targeting agent, polyethyleneimine (a polycation that binds DNA and enhances transfection) was conjugated to serum albumin, and the conjugate was aggregated by heating to produce particles of 25-100 microm. The resulting particles bound plasmid DNA avidly, and when injected i.v. in mice, the particles distributed in the peripheral lung tissue in the alveolar interstitium. Particle-bound luciferase plasmid transfected a variety of cell lines in vitro, and after i.v. injection, gene expression was detected exclusively in the lung. Using human growth hormone as the encoded foreign Ag for immunization, i.v. injection of the particle-bound plasmid elicited both pulmonary mucosal and systemic immune responses, whereas naked DNA injected either i.v. or i.m. elicited only systemic responses. Thus, particle-bound plasmid DNA may have utility for genetic immunization by intravascular delivery to the lung and potentially to other organs and tissues.
Subject(s)
Immunity, Mucosal , Lung/immunology , Polyethyleneimine/administration & dosage , Technetium Tc 99m Aggregated Albumin/immunology , Vaccines, DNA/immunology , Amino Acid Sequence , Animals , Antibody Formation/genetics , Cell Line , Cytotoxicity, Immunologic/genetics , DNA/administration & dosage , DNA/immunology , DNA/metabolism , Female , Humans , Immunity, Mucosal/genetics , Lung/metabolism , Lymphocyte Activation/genetics , Male , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Particle Size , Plasmids/administration & dosage , Plasmids/immunology , Plasmids/pharmacokinetics , Polyethyleneimine/pharmacokinetics , T-Lymphocytes, Cytotoxic/immunology , Technetium Tc 99m Aggregated Albumin/administration & dosage , Technetium Tc 99m Aggregated Albumin/pharmacokinetics , Transfection/immunology , Tumor Cells, Cultured , Vaccines, DNA/administration & dosage , Vaccines, DNA/pharmacokineticsABSTRACT
Fish morbidity and mortality events in Chesapeake Bay tributaries have aroused concern over the health of this important aquatic ecosystem. We applied a recently described method for quantifying mRNA of an immunosuppressive cytokine, transforming growth factor-beta (TGF-beta), by reverse transcription quantitative-competitive polymerase chain reaction to a field study of fish health in the Chesapeake Basin, and compared the results to those of a traditional cellular immunoassay macrophage bactericidal activity. We selected the white perch (Morone americana) as the sentinel fish species because of its abundance at all of the collection sites. White perch were sampled from Chesapeake Bay tributaries in June, August, and October 1998. Splenic mononuclear cell TGF-beta mRNA levels increased and anterior kidney macrophage bactericidal activity decreased, particularly in eastern shore tributaries, from June to August and October. The results of the two assays correlated inversely (Kendall's [Tau] b = -0.600; p = 0.0102). The results indicated both temporal and spatial modulation of white perch immune systems in the Chesapeake Basin, and demonstrated the utility of quantitative PCR for TGF-beta as a molecular biomarker for field assessment of teleost fish immune status.
Subject(s)
Fishes/genetics , Transforming Growth Factor beta/genetics , Animals , Ecosystem , Environmental Health , Environmental Monitoring , Fishes/immunology , Fresh Water , Macrophages/immunology , Maryland , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Seawater , Spleen/immunology , Transforming Growth Factor beta/biosynthesisABSTRACT
BACKGROUND: A major challenge of gene therapy is the efficient transfer of genes to cell sites where effective transfection can occur. The impact of jet nebulization on DNA structural and functional integrity has been problematic for the aerosol delivery of genes to pulmonary sites and remains a serious concern for this otherwise promising and noninvasive approach. METHODS: This study examined effects of cationic liposome-DNA formulation on both transfection efficiency (in vitro and in vivo) and jet nebulizer stability. The effects of nebulization and sonication on liposome-DNA particle size characteristics were examined. Electron microscopy of promising formulations was performed using several fixation methods. RESULTS: The cationic lipid bis-guanidinium-tren-cholesterol (BGTC), in combination with the neutral co-lipid dioleoylphosphatidylethanolamine (DOPE), was found to have a degree of stability adequate to permit effective gene delivery by the aerosol route. Optimal ratios of lipids and plasmid DNA were identified. Particle size analysis and ultrastructural studies revealed a remarkably homogeneous population of distinctly liposomal structures correlating with the highest levels of transfection efficiency and nebulizer stability. CONCLUSIONS: Optimizing gene delivery vectors for pulmonary aerosol delivery to respiratory sites must take into account factors other than transfection efficiency in vitro. Effects of liposome-DNA formulation on liposomal morphology (i.e. particle size, multilamellar structure) appear to be relevant to stability during aerosolization. These studies have allowed us to identify formulations that hold promise for successful clinical application of aerosol gene delivery.
Subject(s)
DNA/administration & dosage , DNA/genetics , Gene Transfer Techniques , Aerosols , Cell Line , Chloramphenicol O-Acetyltransferase/genetics , Cholesterol , Cytomegalovirus/genetics , Genes, Reporter , Genetic Vectors , Guanidine , Humans , Liposomes , Lung/enzymology , Microscopy, Electron , Nebulizers and Vaporizers , Phosphatidylethanolamines , Transfection , beta-Galactosidase/geneticsABSTRACT
Renibacterium salmoninarum is a facultative intracellular pathogen often found in host phagocytes where it appears to successfully avoid the host fish's immunological defenses. The objective of this investigation was to determine if soluble extracellular protein (ECP) produced by R. salmoninarum may contribute to the immunomodulation in bacterial kidney disease (BKD) via inhibition of phagocyte respiratory burst and/or phagocytosis mechanisms. Splenic cells from adult brook trout (Salvelinus fontinalis) were incubated with two different concentrations of ECP (0.1 mg/ml and 1.0 mg/ml) and viable R. salmoninarum. Splenic cell cultures were evaluated for respiratory burst activity via flow cytometry with the dichlorofluorescin diacetate (DCF-DA) assay and for phagocytosis via light microscopic assessment of microsphere engulfment. Respiratory burst activity was significantly inhibited in all treatment groups as compared to untreated fish, while no differences were noted in phagocytic activity.
Subject(s)
Bacterial Proteins/toxicity , Gram-Positive Asporogenous Rods/immunology , Gram-Positive Asporogenous Rods/pathogenicity , Phagocytes/drug effects , Phagocytes/immunology , Trout/immunology , Animals , Fish Diseases/etiology , Fish Diseases/immunology , Fish Diseases/microbiology , Fluoresceins , Gram-Positive Bacterial Infections/etiology , Gram-Positive Bacterial Infections/immunology , Gram-Positive Bacterial Infections/veterinary , Kidney Diseases/etiology , Kidney Diseases/immunology , Kidney Diseases/veterinary , Microspheres , Phagocytes/metabolism , Phagocytosis/drug effects , Respiratory Burst/drug effects , Spleen/cytology , Spleen/immunology , Spleen/metabolism , Trout/metabolismABSTRACT
Our objective was to determine the maximum tolerated dose and toxicity of i.v. edatrexate with p.o. leucovorin. Thirty-one adults with advanced solid tumors received edatrexate as a 2-h infusion, once a week for 3 weeks, recycled every 28 days. p.o. leucovorin (10 mg/m2, every 6 h for 10 doses) began 24 h later. All had urinary alkalinization and p.o. hydration. Nine dosage levels ranging from 120 to 3750 mg/m2 were explored. Fatigue, epistaxis, nausea/emesis, mucositis, rash, myalgias, leukopenia, thrombocytopenia, and transient elevations of serum aspartate transferase were observed. Leukoencephalopathy with clinical manifestations occurred in two patients (one had prior cranial irradiation). Pharmacokinetic studies carried out at the 120- and 1080-mg/m2 dose levels revealed no significant difference in the elimination half-life at the two dose levels studied and no significant intrapatient variability between day 1 and day 8 edatrexate administration. Serum edatrexate levels measured using a dihydrofolate reductase inhibition assay correlated with those by high-performance liquid chromatography. Three major and two minor antitumor responses occurred. The maximum tolerated dose was 3750 mg/m2, with grade 3 or 4 leukopenia (one patient), stomatitis (one patient), and leukoencephalopathy (one patient). Because of the occurrence of leukoencephalopathy, further study of high-dose edatrexate with leucovorin rescue is not recommended.
Subject(s)
Aminopterin/analogs & derivatives , Antineoplastic Agents/therapeutic use , Neoplasms/drug therapy , Administration, Oral , Adult , Aged , Aminopterin/administration & dosage , Aminopterin/metabolism , Aminopterin/pharmacokinetics , Aminopterin/therapeutic use , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/metabolism , Antineoplastic Agents/pharmacokinetics , Drug Interactions , Drug Monitoring , Female , Humans , Leucovorin/pharmacology , Leucovorin/therapeutic use , Male , Middle Aged , Neoplasms/metabolismABSTRACT
Isoflavonoids and related compounds such as coumestrol have classically been categorized as phytoestrogens because these environmentally derived substances bind to the estrogen receptor (ER) and increase uterine wet weight in immature rats and mice. Assessment of the binding affinities of isoflavonoids for ER and subsequent effects on uterine growth suggest these compounds are less active estrogens than estradiol and therefore may reduce the risk of developing breast or prostate cancer in humans by preventing estradiol binding to ER. With the renewed interest in the relationships between environmental estrogens and cancer cause and prevention, we assessed the effects of the phytoestrogen coumestrol on uterotropic response in the immature, ovariectomized rat. Our studies demonstrated that in this animal model, coumestrol is an atypical estrogen that does not stimulate uterine cellular hyperplasia. Although acute (subcutaneous injection) or chronic (multiple injection or orally via drinking water) administration of coumestrol significantly increased uterine wet and dry weights, the phytoestrogen failed to increase uterine DNA content. The lack of true estrogenic activity was characterized by the inability of this phytoestrogen to cause cytosolic ER depletion, nuclear ER accumulation, or the stimulation of nuclear type II sites which characteristically precede estrogenic stimulation of cellular DNA synthesis and proliferation. In fact, subcutaneous or oral coumestrol treatment caused an atypical threefold induction of cytosolic ER without corresponding cytosolic depletion and nuclear accumulation of this receptor, and this increased the sensitivity of the uterus to subsequent stimulation by estradiol.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Coumestrol/pharmacology , Estrogens, Non-Steroidal/pharmacology , Ovary/physiology , Receptors, Estrogen/drug effects , Uterus/drug effects , Animals , Binding, Competitive , Dose-Response Relationship, Drug , Evaluation Studies as Topic , Female , Organ Size/drug effects , Ovariectomy , Rats , Rats, Sprague-Dawley , Uterus/growth & developmentABSTRACT
An improved assay for measuring ligand binding to extracted nuclear type II estrogen binding sites which involves preimmobilization on glass fiber filters is described. At least two classes of specific estrogen binding sites have been demonstrated in rat uterus as well as in a variety of other tissues and species and have been designated as type I and type II. Although the endogenous ligand to the type II binding site has recently been identified as methyl p-hydroxyphenyllactate (MeHPLA), tritiated estrogens are generally used for radiolabeling this site due to the susceptibility of MeHPLA to enzymatic hydrolysis in in vitro assays. After extracting the type II site from the nuclear matrix, ligand binding and protein stability appear to be significantly enhanced by first immobilizing the site on an artificial matrix, such as hydroxylapatite, before incubating with radiolabeled ligand. Immobilization of the extracted site on glass fiber filters results in higher specific binding and lower nonspecific binding when compared to hydroxylapatite and a number of other immobilization matrices. The glass fiber ligand exchange procedure for measuring type II binding can also be performed on smaller samples and requires less time than other methods. Type II sites are significantly stabilized when immobilized on glass and exhibit sigmoidal binding curves when incubated with increasing concentrations of [3H]estradiol and [3H]estrone and display inhibition data characteristic of that observed using more traditional assays.(ABSTRACT TRUNCATED AT 250 WORDS)